hotspot -WSS

hotspot

author：focus 2025-10-02 22:26:58 - browse：731

WASHINGTON — For those already felled by fumes from the Brazilian Blowout, it might be small consolation, but lawmakers are pushing ahead with a campaign for better oversight of the beauty business.

Despite its booming growth, the cosmetics industry in the US has been virtually unregulated. The Food, Drug, and Cosmetic Act, adopted in 1938, essentially allowed personal care product companies to self-police.

But rising public concern over bad reactions to makeup, hair dyes, and fragrances, as well as evidence of long-term health risks from some of their chemical contents, has led lawmakers to try to toughen the regulatory framework for the $60 billion enhancement industry.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Fentanyl is making it harder to start addiction treatment

explore

WSS

Cue Health, Covid

FDA poised to publish guidelines for clinical trial diversity

Physicians and social media: If you see something, say something?

Questions and answers about ramping up H5N1 bird flu vaccine

Digital health: a case of mistaken identity

ASCO eve: Let’s set the table for this year's meeting

focus

hotspot

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

5 to watch: Tech startups trying to solve health care's staffing crisis

Apple is now the first public company to be valued at $3 trillion

H5N1 virus can be tracked in retail milk, scientists say

Medical leaders decry Supreme Court decision on affirmative action

Virtual Event: March of the Biosimilars

Hepatitis C has a cure — but many Americans still lack access to it

Making the case for fair compensation in clinical trials

Bright Health sells Medicare Advantage business to Molina

Intermittent fasting comes with a heart risk? Not so fast

knowledge

Liver decline slowed by off

Neuroscience’s long legacy of racism

Plastic surgeons increase patient psychiatric screenings

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Making the case for fair compensation in clinical trials

focus

explore

focus

Wikipedia